Yttrium 90-radiolabelled OTSA 101

Drug Profile

Yttrium 90-radiolabelled OTSA 101

Alternative Names: Frizzled homologue 10 antibodies - OncoTherapy Science; Frizzled-10 antibodies - OncoTherapy Science; Fz-10 antibodies - OncoTherapy Science; FZD10 monoclonal antibodies - OncoTherapy Science; hFz10 antibodies - OncoTherapy Science; OTSA 101 DTPA-90Y; OTSA101; TT641 pAb - OncoTherapy Science

Latest Information Update: 09 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoTherapy Science
  • Developer Centre Leon Berard; OncoTherapy Science
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals; Radiosensitisers
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Synovial sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Synovial sarcoma

Most Recent Events

  • 02 Jun 2017 Efficacy and adverse events data from a phase I trial in Synovial sarcoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 23 Mar 2016 OncoTherapy Science plans a sponsor-initiated clinical trial for Synovial sarcoma in Japan, USA and European Union
  • 22 Feb 2016 Centre Leon Berard completes a phase I trial in Synovial sarcoma in France (NCT01469975,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top